Cost-effectiveness of PET imaging in clinical oncology
- 31 August 1996
- journal article
- review article
- Published by Elsevier BV in Nuclear Medicine and Biology
- Vol. 23 (6), 737-743
- https://doi.org/10.1016/0969-8051(96)00080-7
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Whole-body 18F-fluorodeoxyglucose positron emission tomography in preoperative evaluation of lung cancerThe Lancet, 1994
- Positron emission tomography and breast masses: Comparison with clinical, mammographic, and pathological findingsAnnals of Surgical Oncology, 1994
- Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT.Radiology, 1994
- Assessment of Primary and Metastatic Ovarian Cancer by Positron Emission Tomography (PET) Using 2-[18F]Deoxyglucose (2-[18F]FDG)Gynecologic Oncology, 1993
- Diagnostic Efficacy of PET-FDG Imaging in Solitary Pulmonary NodulesChest, 1993
- Focal pulmonary abnormalities: evaluation with F-18 fluorodeoxyglucose PET scanning.Radiology, 1993
- Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET.Radiology, 1993
- Recurrent rectal cancer and scar: differentiation with PET and MR imaging.Radiology, 1992
- Focusing Technology Assessment Using Medical Decision TheoryMedical Decision Making, 1988
- Therapeutic Decision Making: A Cost-Benefit AnalysisNew England Journal of Medicine, 1975